Detailed Narrative
Strong Q2 FY25 Performance Driven by Exports
Natco Pharma reported a robust Q2 FY25, with consolidated total revenue reaching INR1,434.9 crores, marking a significant 35.3% year-over-year growth. Net profit on a consolidated basis surged by 82% to INR676.5 million (INR67.65 crores). This strong performance was primarily attributed to the export formulation business, complemented by a stable domestic pharma segment. The Board also declared a second interim dividend of INR1.5 per equity share for FY '24, '25.
Revlimid Contribution and Future Outlook
The company confirmed that its Revlimid market share is progressing well, with expectations to capture almost 1/3 of the total market by January. While management expressed confidence for the current financial year regarding Revlimid, they remained cautious about the next year, citing potential price erosion and market dynamics. The contribution from Revlimid in Q2 was indicated to be in the same range as Q1, though specific figures were not disclosed.
Post-Revlimid Pipeline: Semaglutide and Olaparib
Natco Pharma highlighted its strong pipeline to bridge the gap post-Revlimid exclusivity. Semaglutide (Ozempic) is a major focus, with one formulation already settled (two strengths with sole FTF, others shared FTF) and another under litigation (sole FTF). For the Indian market, the company expects to launch Semaglutide post-2026, pending regulatory approval and patent expiry. Olaparib is another significant product, awaiting FDA approval, with a trial date set in 1 to 1.5 years, and is a 50-50 partnership with Alembic.
Strategic Investments and R&D Focus
The company continues to invest heavily in R&D and disruptive ideas, spending INR100-125 crores this quarter on R&D, bio-studies, and exhibit batches. Notable investments include eGenesis, a biotech company focused on organ transplantation, and a CAR-T company in Delhi. Management views these as long-term 'moonshots' with high risk but potentially large payoffs, aiming to build a portfolio of 10-15 such ideas for sustained growth over the next 8-10 years.
Domestic and Emerging Markets Expansion
Natco Pharma is actively expanding its presence in emerging markets, extending its US-developed products to regions like Brazil, Canada, and other ROW markets. The company is focusing on the Middle East, particularly Saudi Arabia, through partnerships and its own subsidiaries in the Philippines and Indonesia. For the domestic business, management expects a compound growth rate of 15-20% over a 2-3 year perspective, driven by new launches, with Semaglutide anticipated to be a significant growth driver.
Crop Health Sciences Business Outlook
The Crop Health Sciences business is currently operating at a loss, estimated at INR40-50 crores annually. However, management has set an internal objective for this segment to break even by March 2026, with profitability targeted by March 2027. They anticipate that new product launches and strategic initiatives will drive improvement in this business segment.
Financial Outlook and Acquisition Strategy
The company expects to maintain its operating margin of around 60% for the current and next fiscal years. While overall PAT growth for FY25 is now expected to be 'better than 20%', management remains cautious about specific long-term financial guidance due to market volatility🌐 and price erosion. Natco Pharma holds approximately INR2,600 crores in cash as of September end, with projections of $400-500 million by FY26. The company is actively looking for acquisitions, considering transactions ranging from $3-6 million to potentially up to $300 million, leveraging its strong cash position for strategic growth.